Thermo Fisher to Benefit from $31.3B Filtration Surge and $790M CRISPR Growth
TMO•Thermo Fisher should benefit as the global pharmaceutical filtration market grows at an 8.1% CAGR to 2034 and the bioprocess filtration segment jumps from $6.5B in 2025 to $31.33B by 2034 at 19.1% CAGR. Swedish flu diagnostics and CRISPR platforms are forecast to exceed $210M and $790M by 2031.
1. Filtration Market Expansion
The global pharmaceutical filtration market is projected to grow at an 8.13% CAGR from 2025 to 2034, driven by rising biopharmaceutical demand, CDMO expansion and sterile drug manufacturing. Thermo Fisher, as a leading filtration equipment provider, is positioned to capture increased demand through capacity expansions and targeted acquisitions.
2. Bioprocess Filtration Surge
The sterile bioprocess filtration segment is forecast to jump from $6.50 billion in 2025 to $31.33 billion by 2034 at a 19.13% CAGR, underpinned by vaccine production growth and outsourcing to CMOs and CDMOs. Membrane filters are expected to dominate this segment, favoring Thermo Fisher's existing product portfolio.
3. Sweden Flu Diagnostics Growth
Sweden’s flu diagnostics and treatment market is expected to rise from $172.1 million in 2026 to $210.3 million by 2031 at a 4.1% CAGR, supported by an aging population and centralized healthcare adoption of molecular assays. Thermo Fisher’s molecular diagnostics platforms are among the key technologies being adopted by Swedish healthcare providers.
4. CRISPR-Based Platforms Outlook
The CRISPR-based drug development platforms market should grow at an 11.4% CAGR to reach $0.79 billion by 2031, fueled by precision medicine initiatives and increased gene therapy pipelines. Thermo Fisher’s investment in gene editing tools positions it to benefit from accelerating biotech research demand.
